

## Review Article

# Bifidobacteria-Host Interactions—An Update on Colonisation Factors

Verena Grimm, Christina Westermann, and Christian U. Riedel

*Institute of Microbiology and Biotechnology, University of Ulm, 89068 Ulm, Germany*

Correspondence should be addressed to Christian U. Riedel; [christian.riedel@uni-ulm.de](mailto:christian.riedel@uni-ulm.de)

Received 7 July 2014; Revised 20 August 2014; Accepted 20 August 2014; Published 11 September 2014

Academic Editor: Clara G. de los Reyes-Gavilán

Copyright © 2014 Verena Grimm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bifidobacteria are one of the predominant bacterial groups of the human intestinal microbiota and have important functional properties making them interesting for the food and dairy industries. Numerous *in vitro* and preclinical studies have shown beneficial effects of particular bifidobacterial strains or strain combinations on various health parameters of their hosts. This indicates the potential of bifidobacteria in alternative or supplementary therapeutic approaches in a number of diseased states. Based on these observations, bifidobacteria have attracted considerable interest by the food, dairy, and pharmaceutical industries and they are widely used as so-called probiotics. As a consequence of the rapidly increasing number of available bifidobacterial genome sequences and their analysis, there has been substantial progress in the identification of bifidobacterial structures involved in colonisation of and interaction with the host. With the present review, we aim to provide an update on the current knowledge on the mechanisms by which bifidobacteria colonise their hosts and exert health promoting effects.

## 1. Introduction

**1.1. Host Colonisation by Bifidobacteria.** On a cellular basis, humans can be regarded as superorganisms. As a rough approximation, these super-organisms consist of 90% microbial cells with the vast majority of the microbial diversity being located in the human gastrointestinal tract (GIT) [1]. The development and composition of a normal GIT microbiota is crucial for establishing and maintaining human health and well-being [2–4]. It is generally accepted that, before birth, the intrauterine environment and thus the GIT of the unborn foetus are sterile [4]. During delivery, newborns acquire microorganisms from their mothers faecal, vaginal, and skin microbiota. Interestingly, considerable numbers of bifidobacteria and other components of the infant intestinal microbiota were also isolated from human breast milk [5, 6]. Some of the strains recovered in the mother's milk were identical to those detected in the faecal samples of the infant [7] suggesting that human milk might contribute to the establishment and development of the intestinal microbiota of children.

The succession of colonisation follows more or less a classical pattern with facultative anaerobes such as *Escherichia*

*coli* or *Enterococcus sp.* dominating for the first hours or days. Once these organisms have consumed the residual oxygen in the GIT, strictly anaerobic bacteria including *Bifidobacterium sp.*, *Clostridium sp.*, and *Bacteroides sp.* rapidly become predominant [4]. In naturally delivered, breast-fed children up to 95% of all bacteria are bifidobacteria [8–10] making them by far the predominant bacterial component of the faecal microbiota in this group. The bifidobacteria most frequently isolated from healthy breast-fed infants belong to the species *B. longum*, *B. bifidum*, and *B. breve* [10, 11].

Following the period of exclusive breast-feeding, the composition of the faecal microbiota rapidly changes due to the introduction of solid foods, constant exposure to food-derived and environmental microorganisms, and other factors such as hygiene, antibiotic treatment, and so forth [4, 12]. During the first three years of life, the faecal microbiota then gradually develops into the microbiota of adults [9]. The adult colonic and faecal microbiota is dominated by obligate anaerobes with *Firmicutes* and *Bacteroidetes* together representing more than 80% followed by *Actinobacteria*, which contribute up to 10% to the total bacterial flora. The vast majority (up to 100%) of *Actinobacteria* in faecal samples are representatives of the genus *Bifidobacterium* [12].

TABLE 1: Factors and medical conditions associated with changes in the composition of the faecal microbiota.

Factor/disease	Effect/observation	References
Caesarean section	Higher numbers of the <i>Clostridium difficile</i> group I Delayed/reduced colonisation with <i>Bifidobacterium sp.</i> , <i>Lactobacillus sp.</i> and <i>Bacteroides sp.</i>	[14–16]
Infant feeding	Formula-fed infants with lower levels and diversity in <i>Bifidobacterium sp.</i>	[11, 15, 17]
Ageing	Increase in <i>Enterobacteriaceae</i> and <i>Bacteroidetes</i> Reduced levels of <i>Bifidobacterium sp.</i>	[18, 19]
Antibiotic-associated diarrhea and chronic <i>C. difficile</i> infections	Reduced diversity Increase in <i>Enterobacteriaceae</i> and <i>Firmicutes</i> Reduced levels of <i>Bifidobacterium sp.</i> and <i>Bacteroidetes</i>	[18, 20–22]
Irritable bowel syndrome	Increase in <i>Firmicutes</i> Reduced levels of <i>Bacteroidetes</i> and <i>Bifidobacterium sp.</i>	[23–25]
Inflammatory bowel disease	Reduced diversity Lower levels of <i>Faecalibacterium sp.</i> Increase in <i>Enterobacteriaceae</i> and <i>Bifidobacterium sp.</i> Reduced levels of <i>Bifidobacterium sp.</i> in pediatric IBD	[26–29]
Atopic disease/Allergy	Increase in <i>Clostridium sp.</i> Reduced levels of <i>Bifidobacterium sp.</i>	[30–32]
Autism	Increase in <i>Clostridium sp.</i> Reduced levels of <i>Bifidobacterium sp.</i>	[33–35]

Members of this genus are nonmotile, non-spore-forming, strictly anaerobic, gram-positive bacteria characterised by genomes with a high G + C content, an unusual pathway for sugar fermentation termed bifidus shunt, and an unusual V- or Y-shaped morphology formed by most strains under specific culture conditions [13].

**1.2. Effects of *Bifidobacteria* on Host Health.** In healthy individuals, the composition of the intestinal microbiota is relatively stable throughout adulthood with minor day-to-day variations [36, 37]. However, a number of factors have profound impact on the composition of the microbiota and more substantial and persistent changes in the microbiota, a state also termed dysbiosis, are associated with various diseases [2, 38]. A common feature of most diseases with changes in the (intestinal) microbiota is a reduction or change in the relative abundance of bifidobacteria along with an increase in other bacterial groups, such as *Enterobacteriaceae* or clostridia (Table 1). These alterations might be implicated in onset, perpetuation, and/or progression of disease [12]. However, in most cases, it is not clear whether the altered community profiles of the microbiota are a cause or consequence of the disease.

Besides the implication in various diseases, the intestinal microbiota in general and bifidobacteria in particular are important to establish and maintain health of the host. Studies in germ-free animals nicely illustrate that the presence of a normal microbiota is required for proper development and function of the immune and digestive systems (reviewed in [38, 39]). Their predominance during neonatal development suggests that bifidobacteria play a major role in this process [4].

Various beneficial effects have been claimed to be related to presence or administration of bifidobacteria including cholesterol reduction, improvement of lactose intolerance, alleviation of constipation, and immunomodulation [13, 40, 41]. Different strains of bifidobacteria were shown to have profound effects on dendritic cells, macrophage, and T cells of healthy humans and in animals models of allergy or intestinal inflammation [42–47]. One class of molecules that seems to be of particular relevance for the immunomodulatory properties of bifidobacteria is exopolysaccharides (EPS). Mutants of *B. breve* UCC2003 that lack EPS production induce higher numbers of neutrophils, macrophages, NK, T and B cells in mice compared to the wild type strain indicating that EPS production renders this strain less immunogenic by an unknown mechanism [48].

A promising target for bifidobacterial treatments are amelioration of chronic inflammatory disorders of the GIT [42, 49, 50]. Different strains of bifidobacteria were shown to dampen NF- $\kappa$ B activation and expression and secretion of proinflammatory cytokines by IECs or immune cells in response to challenge with LPS, TNF- $\alpha$ , or IL-1 $\beta$  [51–56]. Also, various strains of bifidobacteria or mixes of probiotics containing bifidobacteria were able to counteract intestinal inflammation in different models of chronic intestinal inflammation [49, 53, 55–60]. In murine models, different strains of bifidobacteria have been shown to be able to counteract chronic intestinal inflammation by reducing proinflammatory Th1 and inducing regulatory T-cell populations and lowering of colitogenic bacteria [42, 45, 46, 50, 60].

Experiments in mice indicate that some strains of bifidobacteria confer resistance against infections with *Salmonella enterica* serovar Typhimurium [61], enteropathogenic *E. coli* [62, 63], or *Yersinia enterocolitica* [64]. Interestingly,




FIGURE 1: Host colonisation factors of bifidobacteria identified by genome analysis and supported by experimental evidence obtained in *in vitro* experiments and/or murine model systems (bile-AA: conjugated bile acids; bile-COO<sup>-</sup>: deconjugated bile acids; Tad: tight adherence; EPS: exopolysaccharides; HMO: human milk oligosaccharides).

*B. breve* UCC2003 is able to protect mice against infections with *C. rodentium* and this ability depends on EPS production [48, 65]. The protective effect of other bifidobacteria towards enteric infections and intestinal inflammation was shown to be mediated by the production of short chain fatty acids, that is, the end products of bifidobacterial sugar fermentation [50, 63]. It is thus likely that the contribution of EPS production by *B. breve* UCC2003 to protection against *C. rodentium* is related to the improved colonisation [48].

## 2. Colonisation Factors of Bifidobacteria

Due to the aforementioned effects of bifidobacteria, genomic approaches were pursued to understand the genetic and physiological traits involved in colonisation of and interaction with the host. The first genome sequence of a *Bifidobacterium* sp. strain was published in 2002 [66]. Since

then, the genomes of over 200 strains of bifidobacteria belonging to 25 species and 5 subspecies have been sequenced (<http://www.genomesonline.org/>). Of these bifidobacterial genomes, 37 are complete and published and 42 are available as permanent drafts. Analysis of these genome sequences has provided insights into the very intimate association of bifidobacteria with their hosts and the adaptation to their gastrointestinal habitat and has led to the identification of a large number of genes with a potential role in these processes [67]. Some of these factors have been analysed in more detail (summarized in Figure 1).

**2.1. Resistance to Bile.** Bile salts are detergents that are synthesized in the liver from cholesterol and secreted via the gall bladder into the GIT lumen [68]. They exert various physiological functions including lipid absorption and cholesterol homeostasis [69]. Since bile salts have considerable

antimicrobial activity at physiological concentrations [70], resistance to bile is important for colonisation and persistence of gastrointestinal microorganisms and is thus one of the criteria for the selection of novel probiotic strains [71]. In a number of bifidobacteria, several genes and proteins conferring bile resistance including bile salt hydrolases and bile efflux transporters were identified and characterised *in vitro* [72–82]. Interestingly, the F<sub>1</sub>F<sub>0</sub>-type ATPase of *B. animalis* IPLA4549 was also shown to be involved in bile resistance [83]. The only example for *in vivo* functionality, however, is a recombinant strain of *B. breve* UCC2003 expressing the bile salt hydrolase BilE of *Listeria monocytogenes* [84]. Compared to the wild type, this strain showed improved bile resistance *in vitro* and prolonged gastrointestinal persistence and protection against *L. monocytogenes* infections in mice.

**2.2. Carbohydrate Utilisation.** The genome sequences of bifidobacteria of human origin display a remarkable enrichment in genes involved in breakdown, uptake, and utilisation of a wide variety of complex polysaccharides of dietary and host origin [13, 85–92]. Since most of the simple carbohydrates are absorbed by the host or metabolised by bacteria in the upper gastrointestinal tract, this can be regarded as a specific adaptation of bifidobacteria to their colonic habitat. The ability of bifidobacteria to ferment these complex carbohydrates is the rationale for the use of prebiotics, that is, nondigestible oligosaccharides, to boost bifidobacterial populations in the GIT [93].

The ability to utilise human milk oligosaccharides (HMOs) is thought to provide a selective advantage to bifidobacteria over other microorganisms during initial colonisation of breast-fed newborns and to be, at least partially, responsible for the dominance of bifidobacteria in these children [85, 91]. The genomes of bifidobacteria particularly abundant in breast-fed infants, especially *B. longum* subsp. *infantis*, reflect their adaptation to the utilisation of HMOs [89, 90, 94] and some of the enzymes involved have been characterised [95–97].

Another nutritional adaptation of bifidobacteria to the intestinal niche is the ability to degrade and ferment host-derived mucins. Mucins are high molecular weight glycoproteins secreted by goblet cells as a protective coating for the intestinal epithelium [98]. Similar to the HMO-degradation pathways of *B. longum* subsp. *infantis*, *B. bifidum* strains were shown to grow on mucin as sole carbon source and harbour the respective genes for mucin degradation [85, 92].

**2.3. Adhesins.** Another property frequently associated with host colonisation of commensal and probiotic bacteria is adhesion to intestinal epithelial cells, mucus, or components of the extracellular matrix [99, 100]. Although definite proof for a role of adhesion of bifidobacteria to host-structures in colonisation is missing, these properties are thought to contribute to prolonged persistence and pathogen exclusion. Moreover, the presence of various receptors on the host surface for molecules of probiotic bacteria suggests direct interactions at least at some stage [101].

Strain-dependent adhesion of bifidobacteria to cultured intestinal epithelial cells has been shown in a number of studies [56, 102–115]. However, there are only very few reports investigating adhesion of bifidobacteria from a mechanistic point of view. For example, enolase was shown to mediate binding to human plasminogen by different bifidobacteria [104]. DnaK is another plasminogen-binding protein of *B. animalis* subsp. *lactis* Bl07 [105] and transaldolase is involved in mucus binding of four *B. bifidum* strains [116]. Using a proteomic approach, some of these proteins were shown to be induced in *B. longum* NCC2705 upon cocultivation with intestinal epithelial cells *in vitro* [117]. This indicates that bifidobacteria might be able to sense the presence of intestinal epithelial cells and react by expressing adhesive molecules that mediate interaction with these cells. Interestingly, the role of all these proteins as adhesins seems to be rather a moonlighting function, since they are cytoplasmic proteins with a primary role in bacterial metabolism. Similar moonlighting proteins have been shown to be involved in virulence of different pathogenic bacteria [118].

Bbif.0636, also termed BopA, is a lipoprotein with a cell wall anchor and was previously shown to be involved in adhesion of *B. bifidum* MIMBb75 to IECs [109]. A more detailed analysis performed by our group found the corresponding *bopA* gene to be specifically present in the genomes of *B. bifidum* strains. A purified BopA fusion protein with an N-terminal His<sub>6</sub>-tag inhibited adhesion of *B. bifidum* S17 to IECs. Moreover, expression of this His-tagged protein enhanced adhesion of *B. bifidum* S17 and *B. longum* E18 to IECs. The *bopA* gene is part of an operon encoding a putative oligopeptide ABC transporter and BopA contains an ABC transporter solute-binding domain [109, 112]. This indicates that its primary role might be uptake of nutrients and suggests a moonlighting function in adhesion. A recent study questioned the role of BopA as an adhesin [119]. The authors could show that neither BopA antiserum nor C-terminal His<sub>6</sub>-BopA fusion protein had an effect on adhesion of two *B. bifidum* strains to IECs. However, the His<sub>6</sub>-BopA fusion protein used in this study lacked both the signal sequence and the cell wall anchor motif. Thus, further experiments have to be performed to clarify the role of the position of the His<sub>6</sub>-tag, the contribution of the signal sequence and cell wall anchor, and BopA as an adhesin in general.

A recent bioinformatic analysis of the genome sequence of *B. bifidum* S17 for genetic traits potentially involved in interactions with host tissues revealed that the genome of *B. bifidum* S17 contains at least 10 genes that encode for proteins with domains that have been described or suspected to interact with host tissue components and may thus serve as potential surface-displayed adhesins [120]. Most of the genes for the putative adhesins of *B. bifidum* S17 are expressed *in vitro*, with higher expression during exponential growth phase [120]. Increased expression of the putative adhesins in exponential growth phase was associated with higher adhesion of *B. bifidum* S17 to Caco-2 cells [120].

**2.4. Pili.** All bifidobacterial genomes sequences analysed so far harbour clusters of genes encoding for Tad and/or sortase

dependent pili [120–123]. For example, *B. bifidum* S17, *B. breve* S27, and *B. longum* E18 all harbour a complete gene locus for Tad pili. By contrast, *B. longum* E18 genome only contains an incomplete gene cluster for sortase-dependent pili suggesting absence of such structures and *B. breve* S27 encodes one gene cluster and *B. bifidum* S17 encodes three complete gene clusters for sortase-dependent pili. For a range of bifidobacteria, expression of the genes of these pili operons under *in vitro* conditions and in the mouse gastrointestinal tract could be demonstrated [120, 121, 123]. Several studies have also shown presence of pili on the surface of bifidobacteria under these conditions using immunogold labelling and transmission electron microscopy [122] or atomic force microscopy [121, 123]. For one strain of *B. breve* it was demonstrated that Tad pili are indeed important for host colonisation in a murine model [122].

**2.5. EPS.** Genes for EPS production were identified in most genome sequences of *Bifidobacterium sp.* strains [124]. The genetic organisation of EPS gene clusters is not well conserved in bifidobacteria and this is reflected by a high structural variability in the EPS of different bifidobacteria [124]. A recent study has indicated that production of EPS by *B. breve* UCC2003 is important for host colonisation [48]. Mutants of *B. breve* UCC2003 that lack EPS production are significantly less resistant to acidic pH and bile. Moreover, these mutants less efficiently colonize the gastrointestinal tract of mice compared to the wild type strain. Also, EPS-deficient mutants were considerably less immunogenic as the wild type in mice as reflected by lower numbers of immune cells in spleens and lower serum titres of specific antibodies.

Hidalgo-Cantabrana and colleagues characterized the EPS of *B. animalis* subsp. *lactis* A1 and isogenic derivatives, which were obtained by exposure of strain A1 to bile salts (strain A1dOx) followed by cultivation for several generations in the absence of bile (strain A1dOxR). The strain A1dOxR displays a ropy phenotype and shows higher expression of a protein involved in rhamnose biosynthesis along with higher rhamnose content in its EPS [125]. Interestingly, these strains elicited different responses by peripheral blood mononuclear cells and isolated lamina propria immune cells of rats [126].

Despite the presence of EPS gene clusters in most bifidobacteria, it remains to be determined experimentally whether all bifidobacteria actually do produce EPS, if this EPS has a role in host colonisation, and how different EPS structures impact the immune response of the host.

**2.6. Other Factors Involved in Host Colonisation.** Besides bile, another important stress encountered by bifidobacteria during gastrointestinal transit and colonisation is acidic pH in the stomach and small intestine. A number of *B. animalis* subsp. *animalis* and *lactis* strains were shown to survive acidic pH in the physiological range (pH 3–5) in a strain-specific manner and tolerant strains exhibited higher ATPase activity at pH 4 than at pH 5 [127]. Ventura et al. identified the *atp* operon encoding the F<sub>1</sub>F<sub>0</sub>-type ATPase of *B. lactis* DSM10140 and were able to show that its expression was markedly increased upon exposure to acidic pH [128]. Similarly, various

ATPase subunits were upregulated in *B. longum* subsp. *longum* NCIMB 8809 in response to acid stress (pH 4.8) as shown by a proteomic approach [129]. This suggests that pH resistance of this strain is inducible and might help to cope with the conditions of the gastrointestinal tract thereby supporting host colonisation. Interestingly, resistance to bile and low pH somehow seems to be connected in the closely related *B. animalis* subsp. *lactis* ILPA 4549. In this strain, expression of the F<sub>1</sub>F<sub>0</sub>-type ATPase and ATPase activity in the membrane was increased in the presence of bile [83]. Moreover, the spontaneous mutant *B. lactis* 4549dOx, which shows increased bile resistance, was also able to better tolerate exposure to acidic pH [83].

More recently, one of the mechanisms by which bifidobacteria might be able to sense their environment and regulate expression of factors important for host colonisation and adaptation to the intestinal niche has been investigated in more detail. A proteomic analysis in *B. longum* NCC2705 identified LuxS as one of the proteins with the most prominent host-induced changes in expression compared to *in vitro* growth [130]. LuxS is an enzyme of the activated methyl cycle of bacteria for recycling of S-adenosylmethionine [131]. By-products of this pathway are autoinducer-2 (AI-2)-like molecules, which are also used by bacteria as signaling molecules and were shown to be involved in biofilm formation, virulence, production of antimicrobials, motility, and genetic competence in a number of gram-positive and gram-negative bacteria [132, 133]. All publicly available genome sequences of bifidobacteria harbour *luxS* homologues, which are functional in the production of AI-2 [134]. Moreover, homologous overexpression of *luxS* in *B. longum* NCC2705 increased AI-2 levels in the supernatant and enhanced biofilm formation [134]. For *B. breve* UCC2003, *luxS* was shown to be important for colonisation of the murine gastrointestinal tract [135].

### 3. Concluding Remarks

Collectively, the available data suggests that individual strains of bifidobacteria exert health-promoting effects on their hosts. An important prerequisite for these effects, is resistance to the conditions of the GIT and, at least, transient colonisation of the host. In recent years, there has been considerable progress in the identification of bifidobacterial structures that play a role in host colonisation and health-promoting effects. However, the vast majority of studies have been performed *in vitro* or in animal models. Based on the fact that they have not been substantiated sufficiently by clinical studies in humans, the European Food Safety Authority has rejected all of the health claims submitted for probiotics. This highlights the need for well-performed clinical trials with a clear definition of target groups and relevant biomarkers and a more detailed analysis of the molecular mechanisms responsible for host colonisation and the positive effects of probiotic bifidobacteria.

## Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

## Acknowledgments

This study was partially funded by the German Academic Exchange Service/Federal Ministry of Education and Research (Grant D/09/04778 to Christian U. Riedel). Christina Westermann was supported by a PhD fellowship of the "Landesgraduierföderung Baden-Württemberg".

## References

- [1] M. Wilson, "The indigenous microbiota of the gastrointestinal tract," in *Bacteriology of Humans: An Ecological Perspective*, M. Wi, Ed., pp. 266–326, Blackwell Publishing, Oxford, UK, 2008.
- [2] J. L. Round and S. K. Mazmanian, "The gut microbiota shapes intestinal immune responses during health and disease," *Nature Reviews Immunology*, vol. 9, no. 5, pp. 313–323, 2009.
- [3] F. Sommer and F. Bäckhed, "The gut microbiota-masters of host development and physiology," *Nature Reviews Microbiology*, vol. 11, pp. 227–238, 2013.
- [4] S. Matamoros, C. Gras-Leguen, F. Le Vacon, G. Potel, and M.-F. de La Cochetiere, "Development of intestinal microbiota in infants and its impact on health," *Trends in Microbiology*, vol. 21, no. 4, pp. 167–173, 2013.
- [5] S. Arbolea, P. Ruas-Madiedo, A. Margolles et al., "Characterization and *in vitro* properties of potentially probiotic *Bifidobacterium* strains isolated from breast-milk," *International Journal of Food Microbiology*, vol. 149, no. 1, pp. 28–36, 2011.
- [6] L. Fernández, S. Langa, V. Martín et al., "The human milk microbiota: origin and potential roles in health and disease," *Pharmacological Research*, vol. 69, pp. 1–10, 2013.
- [7] V. Martín, A. Maldonado-Barragán, L. Moles et al., "Sharing of bacterial strains between breast milk and infant feces," *Journal of Human Lactation*, vol. 28, pp. 36–44, 2012.
- [8] K. Kurokawa, T. Itoh, T. Kuwahara et al., "Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes," *DNA Research*, vol. 14, no. 4, pp. 169–181, 2007.
- [9] T. Yatsuneneko, F. E. Rey, M. J. Manary et al., "Human gut microbiome viewed across age and geography," *Nature*, vol. 486, no. 7402, pp. 222–227, 2012.
- [10] F. Turroni, C. Peano, D. A. Pass et al., "Diversity of bifidobacteria within the infant gut microbiota," *PLoS ONE*, vol. 7, no. 5, Article ID e36957, 2012.
- [11] L. C. Roger, A. Costabile, D. T. Holland, L. Hoyles, and A. L. McCartney, "Examination of faecal *Bifidobacterium* populations in breast- and formula-fed infants during the first 18 months of life," *Microbiology*, vol. 156, no. 11, pp. 3329–3341, 2010.
- [12] C. U. Riedel, A. Schwiertz, and M. Egert, "The stomach and small and large intestinal microbiomes," in *The Human Microbiota and Microbiome*, J. R. Marchesi, Ed., CABI, 2014.
- [13] J.-H. Lee and D. J. O'Sullivan, "Genomic insights into bifidobacteria," *Microbiology and Molecular Biology Reviews*, vol. 74, no. 3, pp. 378–416, 2010.
- [14] M.-M. Grönlund, O.-P. Lehtonen, E. Eerola, and P. Kero, "Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 28, no. 1, pp. 19–25, 1999.
- [15] J. Penders, C. Thijs, C. Vink et al., "Factors influencing the composition of the intestinal microbiota in early infancy," *Pediatrics*, vol. 118, no. 2, pp. 511–521, 2006.
- [16] G. Biasucci, M. Rubini, S. Riboni, L. Morelli, E. Bessi, and C. Retetangos, "Mode of delivery affects the bacterial community in the newborn gut," *Early Human Development*, vol. 86, supplement 1, pp. S13–S15, 2010.
- [17] E. Bezirtzoglou, A. Tsiotsias, and G. W. Welling, "Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH)," *Anaerobe*, vol. 17, no. 6, pp. 478–482, 2011.
- [18] M. J. Hopkins, R. Sharp, and G. T. Macfarlane, "Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles," *Gut*, vol. 48, no. 2, pp. 198–205, 2001.
- [19] M. J. Claesson, S. Cusack, O. O'Sullivan et al., "Composition, variability, and temporal stability of the intestinal microbiota of the elderly," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 1, pp. 4586–4591, 2011.
- [20] L. Dethlefsen and D. A. Relman, "Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, supplement, no. 1, pp. 4554–4561, 2011.
- [21] A. R. Manges, A. Labbe, V. G. Loo et al., "Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial *Clostridium difficile*-associated disease," *Journal of Infectious Diseases*, vol. 202, no. 12, pp. 1877–1884, 2010.
- [22] C. Vincent, D. A. Stephens, V. G. Loo et al., "Reductions in intestinal Clostridiales precede the development of nosocomial *Clostridium difficile* infection," *Microbiome*, vol. 1, article 18, 2013.
- [23] A. P. M. Kerckhoffs, M. Samsom, M. E. van der Rest et al., "Lower *Bifidobacteria* counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients," *World Journal of Gastroenterology*, vol. 15, no. 23, pp. 2887–2892, 2009.
- [24] I. B. Jeffery, P. W. O'Toole, L. Öhman et al., "An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota," *Gut*, vol. 61, no. 7, pp. 997–1006, 2012.
- [25] M. Rajilić-Stojanović, E. Biagi, H. G. H. J. Heilig et al., "Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome," *Gastroenterology*, vol. 141, no. 5, pp. 1792–1801, 2011.
- [26] B. P. Willing, J. Dicksved, J. Halfvarson et al., "A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes," *Gastroenterology*, vol. 139, no. 6, pp. 1844.e1–1854.e1, 2010.
- [27] P. Lepage, R. Hösler, M. E. Spehlmann et al., "Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis," *Gastroenterology*, vol. 141, no. 1, pp. 227–236, 2011.
- [28] A. Schwiertz, M. Jacobi, J.-S. Frick, M. Richter, K. Rusch, and H. Köhler, "Microbiota in pediatric inflammatory bowel disease," *Journal of Pediatrics*, vol. 157, no. 2, pp. 240.e1–244.e1, 2010.

- [29] D. N. Frank, A. L. St. Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 34, pp. 13780–13785, 2007.
- [30] J. Penders, C. Thijs, P. A. Van Den Brandt et al., "Gut microbiota composition and development of atopic manifestations in infancy: the KOALA birth cohort study," *Gut*, vol. 56, no. 5, pp. 661–667, 2007.
- [31] M. Kalliomäki, P. Kirjavainen, E. Eerola, P. Kero, S. Salminen, and E. Isolauri, "Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing," *Journal of Allergy and Clinical Immunology*, vol. 107, no. 1, pp. 129–134, 2001.
- [32] B. Björkstén, E. Sepp, K. Julge, T. Voor, and M. Mikelsaar, "Allergy development and the intestinal microflora during the first year of life," *Journal of Allergy and Clinical Immunology*, vol. 108, no. 4, pp. 516–520, 2001.
- [33] M. de Angelis, M. Piccolo, L. Vannini et al., "Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified," *PLoS ONE*, vol. 8, Article ID e76993, 2013.
- [34] J. B. Adams, L. J. Johansen, L. D. Powell, D. Quig, and R. A. Rubin, "Gastrointestinal flora and gastrointestinal status in children with autism—comparisons to typical children and correlation with autism severity," *BMC Gastroenterology*, vol. 11, article 22, 2011.
- [35] H. M. R. T. Parracho, M. O. Bingham, G. R. Gibson, and A. L. McCartney, "Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children," *Journal of Medical Microbiology*, vol. 54, no. 10, pp. 987–991, 2005.
- [36] E. G. Zoetendal, A. D. L. Akkermans, and W. M. De Vos, "Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria," *Applied and Environmental Microbiology*, vol. 64, no. 10, pp. 3854–3859, 1998.
- [37] J. J. Faith, J. L. Guruge, M. Charbonneau et al., "The long-term stability of the human gut microbiota," *Science*, vol. 341, no. 6141, Article ID 1237439, 2013.
- [38] I. Sekirov, S. L. Russell, L. Caetano M Antunes, and B. B. Finlay, "Gut microbiota in health and disease," *Physiological Reviews*, vol. 90, no. 3, pp. 859–904, 2010.
- [39] K. S. B. Bergstrom, V. Kisoos-Singh, D. L. Gibson et al., "Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa," *PLoS Pathogens*, vol. 6, no. 5, Article ID e1000902, 2010.
- [40] S. C. Leahy, D. G. Higgins, G. F. Fitzgerald, and D. van Sinderen, "Getting better with bifidobacteria," *Journal of Applied Microbiology*, vol. 98, no. 6, pp. 1303–1315, 2005.
- [41] C. Picard, J. Fioramonti, A. Francois, T. Robinson, F. Neant, and C. Matuchansky, "Review article: bifidobacteria as probiotic agents—physiological effects and clinical benefits," *Alimentary Pharmacology and Therapeutics*, vol. 22, no. 6, pp. 495–512, 2005.
- [42] S. G. Jeon, H. Kayama, Y. Ueda et al., "Probiotic *Bifidobacterium breve* induces IL-10-producing Tr1 cells in the colon," *PLoS Pathogens*, vol. 8, no. 5, Article ID e1002714, 2012.
- [43] H. Kayama, Y. Ueda, Y. Sawa et al., "Intestinal CX3CR1 high (CX3CR1 high) myeloid cells prevent T-cell-dependent colitis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 13, pp. 5010–5015, 2012.
- [44] A. L. Hart, K. Lammers, P. Brigidi et al., "Modulation of human dendritic cell phenotype and function by probiotic bacteria," *Gut*, vol. 53, no. 11, pp. 1602–1609, 2004.
- [45] P. Konieczna, D. Groeger, M. Ziegler et al., "*Bifidobacterium infantis* 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells," *Gut*, vol. 61, no. 3, pp. 354–366, 2012.
- [46] A. Lyons, D. O'Mahony, F. O'Brien et al., "Bacterial strain-specific induction of Foxp3<sup>+</sup> T regulatory cells is protective in murine allergy models," *Clinical and Experimental Allergy*, vol. 40, no. 5, pp. 811–819, 2010.
- [47] P. López, I. González-Rodríguez, M. Gueimonde, A. Margolles, and A. Suárez, "Immune response to *Bifidobacterium bifidum* strains support Treg/Th17 plasticity," *PLoS ONE*, vol. 6, no. 9, Article ID e24776, 2011.
- [48] S. Fanning, L. J. Hall, M. Cronin et al., "Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 6, pp. 2108–2113, 2012.
- [49] C. Di Giacinto, M. Marinaro, M. Sanchez, W. Strober, and M. Boirivant, "Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF- $\beta$ -bearing regulatory cells," *Journal of Immunology*, vol. 174, no. 6, pp. 3237–3246, 2005.
- [50] P. Veiga, C. A. Gallini, C. Beal et al., "*Bifidobacterium animalis* subsp. *lactis* fermented milk product reduces inflammation by altering a niche for colitogenic microbes," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 42, pp. 18132–18137, 2010.
- [51] C. U. Riedel, F. Foata, D. Philippe, O. Adolffson, B. J. Eikmanns, and S. Blum, "Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF- $\kappa$ B activation," *World Journal of Gastroenterology*, vol. 12, no. 23, pp. 3729–3735, 2006.
- [52] K. M. Lammers, U. Helwig, E. Swennen et al., "Effect of probiotic strains on interleukin 8 production by HT29/19A cells," *The American Journal of Gastroenterology*, vol. 97, no. 5, pp. 1182–1186, 2002.
- [53] S. W. Kim, H. M. Kim, K. M. Yang et al., "*Bifidobacterium lactis* inhibits NF- $\kappa$ B in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice," *Inflammatory Bowel Diseases*, vol. 16, no. 9, pp. 1514–1525, 2010.
- [54] S. Ménard, C. Candalh, J. C. Bambou, K. Terpend, N. Cerf-Bensussan, and M. Heyman, "Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport," *Gut*, vol. 53, no. 6, pp. 821–828, 2004.
- [55] E. Heuvelin, C. Lebreton, C. Grangette, B. Pot, N. Cerf-Bensussan, and M. Heyman, "Mechanisms involved in alleviation of intestinal inflammation by *bifidobacterium breve* soluble factors," *PLoS ONE*, vol. 4, no. 4, Article ID e5184, 2009.
- [56] J. Preising, D. Philippe, M. Gleinser et al., "Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis," *Applied and Environmental Microbiology*, vol. 76, no. 9, pp. 3048–3051, 2010.
- [57] D. Philippe, E. Heupel, S. Blum-Sperisen, and C. U. Riedel, "Treatment with *Bifidobacterium bifidum* 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis," *International Journal of Food Microbiology*, vol. 149, no. 1, pp. 45–49, 2011.

- [58] J. McCarthy, L. O'Mahony, L. O'Callaghan et al., "Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance," *Gut*, vol. 52, no. 7, pp. 975–980, 2003.
- [59] J. B. Ewaschuk, H. Diaz, L. Meddings et al., "Secreted bioactive factors from *Bifidobacterium infantis* enhance epithelial cell barrier function," *The American Journal of Physiology—Gastrointestinal and Liver Physiology*, vol. 295, no. 5, pp. G1025–G1034, 2008.
- [60] H.-K. Kwon, C.-G. Lee, J.-S. So et al., "Generation of regulatory dendritic cells and CD4<sup>+</sup>Foxp3<sup>+</sup> T cells by probiotics administration suppresses immune disorders," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 5, pp. 2159–2164, 2010.
- [61] T. Asahara, K. Nomoto, K. Shimizu, M. Watanuki, and R. Tanaka, "Increased resistance of mice to salmonella enterica serovar typhimurium infection by synbiotic administration of bifidobacteria and transgalactosylated oligosaccharides," *Journal of Applied Microbiology*, vol. 91, no. 6, pp. 985–996, 2001.
- [62] T. Asahara, K. Shimizu, K. Nomoto, T. Hamabata, A. Ozawa, and Y. Takeda, "Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing *Escherichia coli* O157:H7," *Infection and Immunity*, vol. 72, no. 4, pp. 2240–2247, 2004.
- [63] S. Fukuda, H. Toh, K. Hase et al., "Bifidobacteria can protect from enteropathogenic infection through production of acetate," *Nature*, vol. 469, no. 7331, pp. 543–547, 2011.
- [64] J. S. Frick, K. Fink, F. Kahl et al., "Identification of commensal bacterial strains that modulate *Yersinia enterocolitica* and dextran sodium sulfate-induced inflammatory responses: implications for the development of probiotics," *Infection and Immunity*, vol. 75, no. 7, pp. 3490–3497, 2007.
- [65] J. W. Collins, A. R. Akin, A. Kosta et al., "Pre-treatment with *Bifidobacterium breve* UCC2003 modulates *Citrobacter rodentium*-induced colonic inflammation and organ specificity," *Microbiology*, vol. 158, no. 11, pp. 2826–2834, 2012.
- [66] M. A. Schell, M. Karmirantzou, B. Snel et al., "The genome sequence of *Bifidobacterium longum* reflects its adaptation to the human gastrointestinal tract," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 22, pp. 14422–14427, 2002.
- [67] M. Ventura, S. O'Flaherty, M. J. Claesson et al., "Genome-scale analyses of health-promoting bacteria: probiogenomics," *Nature Reviews Microbiology*, vol. 7, no. 1, pp. 61–71, 2009.
- [68] A. F. Hofmann, "The enterohepatic circulation of bile acids in mammals: form and functions," *Frontiers in Bioscience*, vol. 14, no. 7, pp. 2584–2598, 2009.
- [69] P. B. Hylemon, H. Zhou, W. M. Pandak, S. Ren, G. Gil, and P. Dent, "Bile acids as regulatory molecules," *Journal of Lipid Research*, vol. 50, no. 8, pp. 1509–1520, 2009.
- [70] M. Begley, C. G. M. Gahan, and C. Hill, "The interaction between bacteria and bile," *FEMS Microbiology Reviews*, vol. 29, no. 4, pp. 625–651, 2005.
- [71] M. Begley, C. Hill, and C. G. M. Gahan, "Bile salt hydrolase activity in probiotics," *Applied and Environmental Microbiology*, vol. 72, no. 3, pp. 1729–1738, 2006.
- [72] L. Ruiz, M. O'Connell-Motherway, A. Zomer, C. G. de los Reyes-Gavilán, A. Margolles, and D. van Sinderen, "A bile-inducible membrane protein mediates bifidobacterial bile resistance," *Microbial Biotechnology*, vol. 5, no. 4, pp. 523–535, 2012.
- [73] L. Ruiz, A. Zomer, M. O'Connell-Motherway, D. van Sinderen, and A. Margolles, "Discovering novel bile protection systems in *Bifidobacterium breve* UCC2003 through functional genomics," *Applied and Environmental Microbiology*, vol. 78, no. 4, pp. 1123–1131, 2012.
- [74] M. Gueimonde, C. Garrigues, D. van Sinderen, C. G. de los Reyes-Gavilán, and A. Margolles, "Bile-inducible efflux transporter from *Bifidobacterium longum* NCC2705, conferring bile resistance," *Applied and Environmental Microbiology*, vol. 75, no. 10, pp. 3153–3160, 2009.
- [75] G.-B. Kim and B. H. Lee, "Genetic analysis of a bile salt hydrolase in *Bifidobacterium animalis* subsp. *lactis* KL612," *Journal of Applied Microbiology*, vol. 105, no. 3, pp. 778–790, 2008.
- [76] P. Jarocki, "Molecular characterization of bile salt hydrolase from *bifidobacterium animalis* subsp. *lactis* Bi30," *Journal of Microbiology and Biotechnology*, vol. 21, no. 8, pp. 838–845, 2011.
- [77] J.-P. Grill, F. Schneider, J. Crociani, and J. Ballongue, "Purification and characterization of conjugated bile salt hydrolase from *Bifidobacterium longum* BB536," *Applied and Environmental Microbiology*, vol. 61, no. 7, pp. 2577–2582, 1995.
- [78] G.-B. Kim, C. M. Miyamoto, E. A. Meighen, and B. H. Lee, "Cloning and characterization of the bile salt hydrolase genes (*bsh*) from *Bifidobacterium bifidum* strains," *Applied and Environmental Microbiology*, vol. 70, no. 9, pp. 5603–5612, 2004.
- [79] G.-B. Kim, S.-H. Yi, and B. H. Lee, "Purification and characterization of three different types of bile salt hydrolases from *Bifidobacterium* strains," *Journal of Dairy Science*, vol. 87, no. 2, pp. 258–266, 2004.
- [80] G.-B. Kim, M. Brochet, and B. H. Lee, "Cloning and characterization of a bile salt hydrolase (*bsh*) from *Bifidobacterium adolescentis*," *Biotechnology Letters*, vol. 27, no. 12, pp. 817–822, 2005.
- [81] H. Tanaka, H. Hashiba, J. Kok, and I. Mierau, "Bile salt hydrolase of *Bifidobacterium longum*: biochemical and genetic characterization," *Applied and Environmental Microbiology*, vol. 66, no. 6, pp. 2502–2512, 2000.
- [82] C. G. M. Gahan and C. Hill, "Gastrointestinal phase of *Listeria monocytogenes* infection," *Journal of Applied Microbiology*, vol. 98, no. 6, pp. 1345–1353, 2005.
- [83] B. Sánchez, C. G. De Los Reyes-Gavilán, and A. Margolles, "The F1F0-ATPase of *Bifidobacterium animalis* is involved in bile tolerance," *Environmental Microbiology*, vol. 8, no. 10, pp. 1825–1833, 2006.
- [84] D. Watson, R. D. Sleator, C. Hill, and C. G. M. Gahan, "Enhancing bile tolerance improves survival and persistence of *Bifidobacterium* and *Lactococcus* in the murine gastrointestinal tract," *BMC Microbiology*, vol. 8, article 176, 2008.
- [85] M. Ventura, F. Turrone, M. O. Motherway, J. MacSharry, and D. van Sinderen, "Host-microbe interactions that facilitate gut colonization by commensal bifidobacteria," *Trends in Microbiology*, vol. 20, no. 10, pp. 467–476, 2012.
- [86] D. Zhurina, A. Dudnik, M. S. Waidmann et al., "High-quality draft genome sequence of *bifidobacterium longum* E18, isolated from a healthy adult," *Genome Announcements*, vol. 1, no. 6, 2013.
- [87] D. Zhurina, A. Zomer, M. Gleinser et al., "Complete genome sequence of *Bifidobacterium bifidum* S17," *Journal of Bacteriology*, vol. 193, no. 1, pp. 301–302, 2011.
- [88] F. Bottacini, M. O'Connell Motherway, J. Kuczynski et al., "Comparative genomics of the *Bifidobacterium breve* taxon," *BMC Genomics*, vol. 15, article 170, 2014.



- [89] D. A. Sela, J. Chapman, A. Adeuya et al., "The genome sequence of *Bifidobacterium longum* subsp. *infantis* reveals adaptations for milk utilization within the infant microbiome," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 48, pp. 18964–18969, 2008.
- [90] D. A. Sela and D. A. Mills, "Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides," *Trends in Microbiology*, vol. 18, no. 7, pp. 298–307, 2010.
- [91] A. Marcobal and J. L. Sonnenburg, "Human milk oligosaccharide consumption by intestinal microbiota," *Clinical Microbiology and Infection*, vol. 18, supplement 4, pp. 12–15, 2012.
- [92] F. Turroni, F. Bottacini, E. Foroni et al., "Genome analysis of *Bifidobacterium bifidum* PRL2010 reveals metabolic pathways for host-derived glycan foraging," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 45, pp. 19514–19519, 2010.
- [93] E. Holmes, J. Kinross, G. R. Gibson et al., "Therapeutic modulation of microbiota-host metabolic interactions," *Science Translational Medicine*, vol. 4, no. 137, Article ID 137rv6, 2012.
- [94] R. G. LoCascio, P. Desai, D. A. Sela, B. Weimer, and D. A. Mills, "Broad conservation of milk utilization genes in *Bifidobacterium longum* subsp. *infantis* as revealed by comparative genomic hybridization," *Applied and Environmental Microbiology*, vol. 76, no. 22, pp. 7373–7381, 2010.
- [95] D. A. Sela, D. Garrido, L. Lerno et al., "*Bifidobacterium longum* subsp. *infantis* ATCC 15697  $\alpha$ -fucosidases are active on fucosylated human milk oligosaccharides," *Applied and Environmental Microbiology*, vol. 78, no. 3, pp. 795–803, 2012.
- [96] D. Garrido, C. Nwosu, S. Ruiz-Moyano et al., "Endo- $\beta$ -N-acetylglucosaminidases from infant gut-associated bifidobacteria release complex N-glycans from human milk glycoproteins," *Molecular and Cellular Proteomics*, vol. 11, no. 9, pp. 775–785, 2012.
- [97] E. Yoshida, H. Sakurama, M. Kiyohara et al., "*Bifidobacterium longum* subsp. *infantis* uses two different  $\beta$ -galactosidases for selectively degrading type-1 and type-2 human milk oligosaccharides," *Glycobiology*, vol. 22, no. 3, pp. 361–368, 2012.
- [98] M. E. V. Johansson, H. Sjövall, and G. C. Hansson, "The gastrointestinal mucus system in health and disease," *Nature Reviews Gastroenterology & Hepatology*, vol. 10, pp. 352–561, 2013.
- [99] J. M. Laparra and Y. Sanz, "Comparison of in vitro models to study bacterial adhesion to the intestinal epithelium," *Letters in Applied Microbiology*, vol. 49, no. 6, pp. 695–701, 2009.
- [100] E. Tuomola, R. Crittenden, M. Playne, E. Isolauri, and S. Salminen, "Quality assurance criteria for probiotic bacteria," *The American Journal of Clinical Nutrition*, vol. 73, no. 2, pp. 393S–398S, 2001.
- [101] S. Lebeer, J. Vanderleyden, and S. C. J. de Keersmaecker, "Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens," *Nature Reviews Microbiology*, vol. 8, no. 3, pp. 171–184, 2010.
- [102] M.-F. Bernet, D. Brassart, J.-R. Neeser, and A. L. Servin, "Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions," *Applied and Environmental Microbiology*, vol. 59, no. 12, pp. 4121–4128, 1993.
- [103] M. Candela, S. Bergmann, M. Vici et al., "Binding of human plasminogen to *Bifidobacterium*," *Journal of Bacteriology*, vol. 189, no. 16, pp. 5929–5936, 2007.
- [104] M. Candela, E. Biagi, M. Centanni et al., "Bifidobacterial enolase, a cell surface receptor for human plasminogen involved in the interaction with the host," *Microbiology*, vol. 155, no. 10, pp. 3294–3303, 2009.
- [105] M. Candela, M. Centanni, J. Fiori et al., "DnaK from *Bifidobacterium animalis* subsp. *lactis* is a surface-exposed human plasminogen receptor upregulated in response to bile salts," *Microbiology*, vol. 156, no. 6, pp. 1609–1618, 2010.
- [106] J. Crociani, J.-P. Grill, M. Huppert, and J. Ballongue, "Adhesion of different bifidobacteria strains to human enterocyte-like Caco-2 cells and comparison with in vivo study," *Letters in Applied Microbiology*, vol. 21, no. 3, pp. 146–148, 1995.
- [107] B. Del Re, B. Sgorbati, M. Miglioli, and D. Palenzona, "Adhesion, autoaggregation and hydrophobicity of 13 strains of *Bifidobacterium longum*," *Letters in Applied Microbiology*, vol. 31, no. 6, pp. 438–442, 2000.
- [108] P. K. Gopal, J. Prasad, J. Smart, and H. S. Gill, "In vitro adherence properties of *Lactobacillus rhamnosus* DR20 and *Bifidobacterium lactis* DR10 strains and their antagonistic activity against an enterotoxigenic *Escherichia coli*," *International Journal of Food Microbiology*, vol. 67, no. 3, pp. 207–216, 2001.
- [109] S. Guglielmetti, I. Tamagnini, D. Mora et al., "Implication of an outer surface lipoprotein in adhesion of *Bifidobacterium bifidum* to Caco-2 cells," *Applied and Environmental Microbiology*, vol. 74, no. 15, pp. 4695–4702, 2008.
- [110] S. Guglielmetti, I. Tamagnini, M. Minuzzo et al., "Study of the adhesion of *Bifidobacterium bifidum* MIMBb75 to human intestinal cell lines," *Current Microbiology*, vol. 59, no. 2, pp. 167–172, 2009.
- [111] C. U. Riedel, F. Foata, D. R. Goldstein, S. Blum, and B. J. Eikmanns, "Interaction of bifidobacteria with Caco-2 cells: adhesion and impact on expression profiles," *International Journal of Food Microbiology*, vol. 110, no. 1, pp. 62–68, 2006.
- [112] M. Gleinser, V. Grimm, D. Zhurina, J. Yuan, and C. U. Riedel, "Improved adhesive properties of recombinant bifidobacteria expressing the *Bifidobacterium bifidum*-specific lipoprotein BopA," *Microbial Cell Factories*, vol. 11, article 80, 2012.
- [113] W.-H. Pan, P.-L. Li, and Z. Liu, "The correlation between surface hydrophobicity and adherence of *Bifidobacterium* strains from centenarians' faeces," *Anaerobe*, vol. 12, no. 3, pp. 148–152, 2006.
- [114] M. Juntunen, P. V. Kirjavainen, A. C. Ouwehand, S. J. Salminen, and E. Isolauri, "Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection," *Clinical and Diagnostic Laboratory Immunology*, vol. 8, no. 2, pp. 293–296, 2001.
- [115] P. V. Kirjavainen, A. C. Ouwehand, E. Isolauri, and S. J. Salminen, "The ability of probiotic bacteria to bind to human intestinal mucus," *FEMS Microbiology Letters*, vol. 167, no. 2, pp. 185–189, 1998.
- [116] I. González-Rodríguez, B. Sánchez, L. Ruiz et al., "Role of extracellular transaldolase from *Bifidobacterium bifidum* in mucin adhesion and aggregation," *Applied and Environmental Microbiology*, vol. 78, no. 11, pp. 3992–3998, 2012.
- [117] X. Wei, X. Yan, X. Chen et al., "Proteomic analysis of the interaction of *Bifidobacterium longum* NCC2705 with the intestine cells Caco-2 and identification of plasminogen receptors," *Journal of Proteomics*, vol. 108, pp. 89–98, 2014.
- [118] B. Henderson and A. Martin, "Bacterial moonlighting proteins and bacterial virulence," *Current Topics in Microbiology and Immunology*, vol. 358, pp. 155–213, 2013.
- [119] V. Kainulainen, J. Reunanen, K. Hiippala et al., "BopA has no major role in the adhesion of *Bifidobacterium bifidum* to intestinal epithelial cells, extracellular matrix proteins and mucus," *Applied and Environmental Microbiology*, 2013.

- [120] C. Westermann, D. S. Zhurina, A. Baur, W. Shang, J. Yuan, and C. U. Riedel, "Exploring the genome sequence of *Bifidobacterium bifidum* S17 for potential players in host-microbe interactions," *Symbiosis*, vol. 58, no. 1-3, pp. 191–200, 2012.
- [121] F. Turrone, F. Serafini, E. Foroni et al., "Role of sortase-dependent pili of *Bifidobacterium bifidum* PRL2010 in modulating bacterium-host interactions," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 27, pp. 11151–11156, 2013.
- [122] M. O. Motherway, A. Zomer, S. C. Leahy et al., "Functional genome analysis of *Bifidobacterium breve* UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 27, pp. 11217–11222, 2011.
- [123] E. Foroni, F. Serafini, D. Amidani et al., "Genetic analysis and morphological identification of pilus-like structures in members of the genus *Bifidobacterium*," *Microbial Cell Factories*, vol. 10, supplement 1, article S16, 2011.
- [124] C. Hidalgo-Cantabrana, B. Sánchez, C. Milani, M. Ventura, A. Margolles, and P. Ruas-Madiedo, "Genomic overview and biological functions of exopolysaccharide biosynthesis in *Bifidobacterium* spp," *Applied and Environmental Microbiology*, vol. 80, pp. 9–18, 2014.
- [125] C. Hidalgo-Cantabrana, B. Sánchez, D. Moine et al., "Insights into the ropy phenotype of the exopolysaccharide-producing strain *Bifidobacterium animalis* subsp. *lactis* A1DOXR," *Applied and Environmental Microbiology*, vol. 79, no. 12, pp. 3870–3874, 2013.
- [126] C. Hidalgo-Cantabrana, M. Nikolic, P. López et al., "Exopolysaccharide-producing *Bifidobacterium animalis* subsp. *lactis* strains and their polymers elicit different responses on immune cells from blood and gut associated lymphoid tissue," *Anaerobe*, vol. 26, pp. 24–30, 2014.
- [127] M. Matsumoto, H. Ohishi, and Y. Benno, "H<sup>+</sup>-ATPase activity in *Bifidobacterium* with special reference to acid tolerance," *International Journal of Food Microbiology*, vol. 93, no. 1, pp. 109–113, 2004.
- [128] M. Ventura, C. Canchaya, D. van Sinderen, G. F. Fitzgerald, and R. Zink, "*Bifidobacterium lactis* DSM 10140: identification of the *atp* (*atpBEFHAGDC*) operon and analysis of its genetic structure, characteristics, and phylogeny," *Applied and Environmental Microbiology*, vol. 70, no. 5, pp. 3110–3121, 2004.
- [129] B. Sánchez, M.-C. Champomier-Vergès, M. D. C. Collado et al., "Low-pH adaptation and the acid tolerance response of *Bifidobacterium longum* biotype *longum*," *Applied and Environmental Microbiology*, vol. 73, no. 20, pp. 6450–6459, 2007.
- [130] J. Yuan, B. Wang, Z. Sun et al., "Analysis of host-inducing proteome changes in *Bifidobacterium longum* NCC2705 grown in vivo," *Journal of Proteome Research*, vol. 7, no. 1, pp. 375–385, 2008.
- [131] N. Parveen and K. A. Cornell, "Methylthioadenosine/S-adenosylhomocysteine nucleosidase, a critical enzyme for bacterial metabolism," *Molecular Microbiology*, vol. 79, no. 1, pp. 7–20, 2011.
- [132] A. Vendeville, K. Winzer, K. Heurlier, C. M. Tang, and K. R. Hardie, "Making 'sense' of metabolism: autoinducer-2, LuxS and pathogenic bacteria," *Nature Reviews Microbiology*, vol. 3, no. 5, pp. 383–396, 2005.
- [133] C. S. Pereira, J. A. Thompson, and K. B. Xavier, "AI-2-mediated signalling in bacteria," *FEMS Microbiology Reviews*, vol. 37, no. 2, pp. 156–181, 2013.
- [134] Z. Sun, X. He, V. F. Brancaccio, J. Yuan, and C. U. Riedel, "Bifidobacteria exhibit luxS-dependent autoinducer 2 activity and biofilm formation," *PLoS ONE*, vol. 9, Article ID e88260, 2014.
- [135] S. E. A. Christiaen, M. O'Connell Motherway, F. Bottacini et al., "Autoinducer-2 plays a crucial role in gut colonization and probiotic functionality of *Bifidobacterium breve* UCC2003," *PLoS One*, vol. 9, Article ID e98111, 2014.